Détention brevets de la classe A61K 31/4465

Brevets de cette classe: 217

Historique des publications depuis 10 ans

14
15
16
16
18
7
9
8
11
8
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Propriétaires principaux

Proprétaire
Total
Cette classe
Theravance Biopharma R&D IP, LLC
457
18
The Regents of the University of California
20153
11
Taisho Pharmaceutical Co., Ltd.
863
8
Board of Regents, The University of Texas System
5891
6
Emory University
1643
5
Bayer Schering Pharma AG
376
3
The Board of Trustees of the Leland Stanford Junior University
6494
3
The Trustees of Columbia University in the City of New York
3597
3
President and Fellows of Harvard College
6009
3
The Trustees of the University of Pennsylvania
4366
3
Kancera AB
33
3
University of Kansas
887
3
Uniwersytet Jagiellonski
263
3
Horizon Orphan LLC.
33
3
Frequency Therapeutics, Inc.
50
3
Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd.
8
3
Bristol-myers Squibb Company
4840
2
F. Hoffmann-La Roche AG
7946
2
Medtronic, Inc.
9829
2
Nitto Denko Corporation
8346
2
Autres propriétaires 128